BioTime offers 5 new human stem cell lines developed using ACTCellerate technology for research use

BioTime, Inc. (AMEX:BTIM) announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells. The new lines will include W10 with markers of smooth muscle progenitors, RASMO12 with unique markers associated with the kidney, U31 with markers associated with the neurotransmitter dopamine useful in research in Parkinson's disease and diseases of the autonomic nervous system, as well as the lines SK11, EN1, and 7SMOO7, properties of which will be disclosed on product launch. BioTime CEO Dr. Michael West will discuss these new products as part of a presentation today at the GTCbio 6th Annual Stem Cell Research & Therapeutics Conference in Boston, Massachusetts. These new cell lines may be purchased beginning June 1, 2010, and additional information about the products may be found, at http://www.embryome.com/products.htm.

Dr. West's presentation at the GTCbio Conference will focus on stem cell differentiation and will describe BioTime's recent efforts to generate highly purified, diverse, and scalable embryonic progenitor (EP) cell types for potential use in human cell therapy, including six cell types with potential use in orthopedic disease. A complete abstract of Dr. West's presentation is available on the conference website at www.gtcbio.com, and a copy of the presentation will be available on BioTime's website at www.biotimeinc.com.

The annual GTCbio Stem Cell Research & Therapeutics Conference provides leading-edge information on developments in all areas of stem cell research, including the biology, medicine, applications, regulations, and business of stem cells. This year's sessions will include discussions of the new federal funding opportunities that are arising as alternative sources of human embryonic stem cells emerge.